177 related articles for article (PubMed ID: 38684283)
1. Oral targeted therapy for the treatment of non-small cell lung carcinoma.
Phillips WJ; Leighl NB; Blais N; Wheatley-Price P
CMAJ; 2024 Apr; 196(16):E558-E561. PubMed ID: 38684283
[No Abstract] [Full Text] [Related]
2. [Not Available].
Phillips WJ; Leighl NB; Blais N; Wheatley-Price P
CMAJ; 2024 Jun; 196(22):E770-E774. PubMed ID: 38857934
[No Abstract] [Full Text] [Related]
3. Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years.
Vansteenkiste J; Wauters E
Ann Oncol; 2018 Jan; 29(suppl_1):i1-i2. PubMed ID: 29462258
[No Abstract] [Full Text] [Related]
4. [Molecular targeted therapies and cytotoxics: Friends or foes?].
Vignot S; Zalcman G
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S91-2. PubMed ID: 26118883
[No Abstract] [Full Text] [Related]
5. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Stinchcombe TE; Ramalingam SS
Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
[No Abstract] [Full Text] [Related]
6. [Not Available].
López-Brea M
Med Clin (Barc); 2016 Apr; 146 Suppl 1():1. PubMed ID: 27426240
[No Abstract] [Full Text] [Related]
7. [EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].
Moldvay J; Peták I
Magy Onkol; 2012 Mar; 56(1):38-49. PubMed ID: 22403761
[TBL] [Abstract][Full Text] [Related]
8. Third-generation EGFR-TKIs—a new hope for NSCLC.
Akkermans R
Lancet Respir Med; 2014 Jul; 2(7):520. PubMed ID: 25140365
[No Abstract] [Full Text] [Related]
9. Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
Saijo N
Nat Rev Clin Oncol; 2010 Nov; 7(11):618-9. PubMed ID: 20981125
[No Abstract] [Full Text] [Related]
10. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
[No Abstract] [Full Text] [Related]
11. Targeted therapies for advanced non-small cell lung cancer.
Starakis I; Nikolakopoulos A; Mazokopakis EE
Comb Chem High Throughput Screen; 2012 Sep; 15(8):641-55. PubMed ID: 22409867
[TBL] [Abstract][Full Text] [Related]
12. Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.
Tang C; Gao H; Li X; Liu Y; Li J; Qin H; Wang W; Qu L; An J; Yang S; Liu X
J Cancer Res Clin Oncol; 2014 Mar; 140(3):427-33. PubMed ID: 24401995
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Qi YT; Hou Y; Qi LC
Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
[TBL] [Abstract][Full Text] [Related]
14. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.
Hong S; Gao F; Fu S; Wang Y; Fang W; Huang Y; Zhang L
JAMA Oncol; 2018 May; 4(5):739-742. PubMed ID: 29596544
[TBL] [Abstract][Full Text] [Related]
15. Medical treatment of non-small-cell lung cancer.
Buter J; Giaccone G
Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
[No Abstract] [Full Text] [Related]
16. [Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer].
Zhang H; Zhang S
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):61-65. PubMed ID: 28103975
[TBL] [Abstract][Full Text] [Related]
17. [Ⅱ. Development Status and Prospect of Molecular Targeted Agents in Non-Small-Cell Lung Cancer].
Kanazu M
Gan To Kagaku Ryoho; 2020 Aug; 47(8):1171-1177. PubMed ID: 32829350
[No Abstract] [Full Text] [Related]
18. [Recent Advances and Prospect of Advanced Non-small Cell Lung Cancer Targeted
Therapy: Focus on Small Molecular Tyrosine Kinase Inhibitors].
Zhang G; Wang H; Ma Z
Zhongguo Fei Ai Za Zhi; 2017 Apr; 20(4):278-286. PubMed ID: 28442018
[TBL] [Abstract][Full Text] [Related]
19. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
Lau SCM; Batra U; Mok TSK; Loong HH
Drugs; 2019 Jun; 79(8):823-831. PubMed ID: 31069718
[TBL] [Abstract][Full Text] [Related]
20. ALK-targeted therapy in NSCLC: likely to be of benefit but not quite ready for prime time.
Socinski MA
Oncology (Williston Park); 2011 Jun; 25(7):601, 604, 607. PubMed ID: 21888259
[No Abstract] [Full Text] [Related]
[Next] [New Search]
